Advanced-stage pancreatic cancer: therapy options

被引：186

作者：

Werner, Jens ^{[1
]}

Combs, Stephanie E. ^{[2
]}

Springfeld, Christoph ^{[3
]}

Hartwig, Werner ^{[1
]}

Hackert, Thilo ^{[1
]}

Buechler, Markus W. ^{[1
]}

机构：

[1] Dept Gen Visceral & Transplantat Surg, D-69120 Heidelberg, Germany

[2] Dept Radiat Oncol, D-69120 Heidelberg, Germany

[3] Heidelberg Univ, Natl Ctr Tumour Dis, D-69120 Heidelberg, Germany

来源：

NATURE REVIEWS CLINICAL ONCOLOGY | 2013年 / 10卷 / 06期

关键词：

PHASE-III TRIAL; QUALITY-OF-LIFE; BODY RADIATION-THERAPY; GEMCITABINE-BASED CHEMORADIATION; ADVANCED DUCTAL ADENOCARCINOMA; ERLOTINIB PLUS GEMCITABINE; CARBON-ION RADIOTHERAPY; LOCALIZED ADENOCARCINOMA; FOLINIC ACID; PERIAMPULLARY ADENOCARCINOMA;

D O I：

10.1038/nrclinonc.2013.66

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Pancreatic ductal adenocarcinoma is one of the most aggressive cancers, and surgical resection is a requirement for a potential cure. However, the majority of patients are diagnosed with advanced-stage disease, either metastatic (50%) or locally advanced cancer (30%). Although palliative chemotherapy is the standard of care for patients with metastatic disease, management of locally advanced adenocarcinoma is controversial. Several treatment options, including extended surgical resections, neoadjuvant therapy with subsequent resections, as well as palliative radiotherapy and/or chemotherapy, should be considered. However, there is little evidence available to support treatment options for locally advanced disease. As valid predictive biomarkers for stratification of therapy are not available today, future trials need to define the role of the different treatment options. This Review summarizes the current evidence and discusses available treatment options for both locally advanced and metastatic pancreatic adenocarcinoma.

引用

页码：323 / 333

页数：11

共 154 条

[1]

Abelson J. A., 2012, INT J RADIAT ONCOL, V15, P82

[2] Carcinoma of the pancreas: summary of guidelines in 2007, issued jointly by 15 German specialist medical societies [J].

Adler, G. ;

Seufferlein, T. ;

Bischoff, S. C. ;

Brambs, H.-J. ;

Feuerbach, S. ;

Grabenbauer, G. ;

Hahn, S. ;

Heinemann, V. ;

Hohenberger, W. ;

Langrehr, J. M. ;

Lutz, M. P. ;

Micke, O. ;

Neuhaus, H. ;

Neuhaus, P. ;

Oettle, H. ;

Schlag, P. M. ;

Schmid, R. ;

Schmiegel, W. ;

Schlottmann, K. ;

Werner, J. ;

Wiedenmann, B. ;

Kopp, I. .

DEUTSCHE MEDIZINISCHE WOCHENSCHRIFT, 2007, 132 (33) :1696-1700

[3] Surgical resection following radiation therapy with concurrent gemcitabine in patients with previously unresectable adenocarcinoma of the pancreas [J].

Ammori, JB ;

Colletti, LM ;

Zalupski, MM ;

Eckhauser, FE ;

Greenson, JK ;

Dimick, Y ;

Lawrence, TS ;

McGinn, CY .

JOURNAL OF GASTROINTESTINAL SURGERY, 2003, 7 (06) :766-772

[4] Neoadjuvant/Preoperative Gemcitabine for Patients with Localized Pancreatic Cancer: A Meta-analysis of Prospective Studies [J].

Andriulli, Angelo ;

Festa, Virginia ;

Botteri, Edoardo ;

Valvano, Maria R. ;

Koch, Maurizio ;

Bassi, Claudio ;

Maisonneuve, Patrick ;

Di Sebastiano, Pierluigi .

ANNALS OF SURGICAL ONCOLOGY, 2012, 19 (05) :1644-1662

[5] Phase II open-label study of erlotinib in combination with gemcitabine in unresectable and/or metastatic adenocarcinoma of the pancreas: relationship between skin rash and survival (Pantar study) [J].

Aranda, E. ;

Manzano, J. L. ;

Rivera, F. ;

Galan, M. ;

Valladares-Ayerbes, M. ;

Pericay, C. ;

Safont, M. J. ;

Mendez, M. J. ;

Irigoyen, A. ;

Arrivi, A. ;

Sastre, J. ;

Diaz-Rubio, E. .

ANNALS OF ONCOLOGY, 2012, 23 (07) :1919-1925

[6]

Baron Todd H, 2004, Gastroenterology, V127, P1268, DOI 10.1053/j.gastro.2004.05.065

[7] CD40 Agonists Alter Tumor Stroma and Show Efficacy Against Pancreatic Carcinoma in Mice and Humans [J].

Beatty, Gregory L. ;

Chiorean, Elena G. ;

Fishman, Matthew P. ;

Saboury, Babak ;

Teitelbaum, Ursina R. ;

Sun, Weijing ;

Huhn, Richard D. ;

Song, Wenru ;

Li, Dongguang ;

Sharp, Leslie L. ;

Torigian, Drew A. ;

O'Dwyer, Peter J. ;

Vonderheide, Robert H. .

SCIENCE, 2011, 331 (6024) :1612-1616

[8] Pancreatic cancer genomes reveal aberrations in axon guidance pathway genes [J].

Biankin, Andrew V. ;

Waddell, Nicola ;

Kassahn, Karin S. ;

Gingras, Marie-Claude ;

Muthuswamy, Lakshmi B. ;

Johns, Amber L. ;

Miller, David K. ;

Wilson, Peter J. ;

Patch, Ann-Marie ;

Wu, Jianmin ;

Chang, David K. ;

Cowley, Mark J. ;

Gardiner, Brooke B. ;

Song, Sarah ;

Harliwong, Ivon ;

Idrisoglu, Senel ;

Nourse, Craig ;

Nourbakhsh, Ehsan ;

Manning, Suzanne ;

Wani, Shivangi ;

Gongora, Milena ;

Pajic, Marina ;

Scarlett, Christopher J. ;

Gill, Anthony J. ;

Pinho, Andreia V. ;

Rooman, Ilse ;

Anderson, Matthew ;

Holmes, Oliver ;

Leonard, Conrad ;

Taylor, Darrin ;

Wood, Scott ;

Xu, Qinying ;

Nones, Katia ;

Fink, J. Lynn ;

Christ, Angelika ;

Bruxner, Tim ;

Cloonan, Nicole ;

Kolle, Gabriel ;

Newell, Felicity ;

Pinese, Mark ;

Mead, R. Scott ;

Humphris, Jeremy L. ;

Kaplan, Warren ;

Jones, Marc D. ;

Colvin, Emily K. ;

Nagrial, Adnan M. ;

Humphrey, Emily S. ;

Chou, Angela ;

Chin, Venessa T. ;

Chantrill, Lorraine A. .

NATURE, 2012, 491 (7424) :399-405

[9] Multimodality therapy for pancreatic cancer in the US - Utilization, outcomes, and the effect of hospital volume [J].

Bilimoria, Karl Y. ;

Bentrem, David J. ;

Ko, Clifford Y. ;

Tomlinson, James S. ;

Stewart, Andrew K. ;

Winchester, David P. ;

Talamonti, Mark S. .

CANCER, 2007, 110 (06) :1227-1234

[10] National failure to operate on early stage pancreatic cancer [J].

Bilimoria, Karl Y. ;

Bentrem, David J. ;

Ko, Clifford Y. ;

Stewart, Andrew K. ;

Winchester, David P. ;

Talamonti, Mark S. .

ANNALS OF SURGERY, 2007, 246 (02) :173-180

← 1 2 3 4 5 6 7 8 9 10 →